Xin Lang Cai Jing·2026-03-18 07:29Core Viewpoint - Kailaiying Pharmaceutical Group is focusing on expanding its CDMO (Contract Development and Manufacturing Organization) services, particularly in the peptide sector, with significant capacity growth expected by mid-2024 [2][12]. Group 1: Company Overview - Kailaiying Pharmaceutical Group (Tianjin) Co., Ltd. provides comprehensive drug lifecycle services for pharmaceutical and biotechnology companies [2][8]. - The company is a leading player in the domestic CMO industry, offering customized R&D and production services, including the development of new drugs for various diseases [2][8]. - As of September 30, 2025, Kailaiying reported a revenue of 4.63 billion yuan, a year-on-year increase of 11.82%, and a net profit of 800 million yuan, up 12.66% [9][18]. Group 2: Business Development - The company is accelerating the construction of its peptide commercialization capacity, aiming for a total solid-phase synthesis capacity of 14,250 liters by June 2024 [2][12]. - Kailaiying has undertaken 12 new projects in the CDMO sector, with the first GLP-1 NDA project preparation underway [2][12]. - The establishment of a synthetic biology technology research center is part of the company's strategy to enhance its capabilities in pharmaceutical and life sciences [3][13]. Group 3: Financial Analysis - The stock's average trading cost is 101.63 yuan, with recent buying activity noted, although the strength of this accumulation is weak [17]. - The stock is currently near a support level of 96.96 yuan, and a drop below this level could trigger a downward trend [17]. - As of the latest data, the main capital inflow was 7.78 million yuan, with a net outflow of 305 million yuan in the industry over three days [4][5][14].